Price cuts boost Novo Nordisk’s Wegovy in India; Mounjaro retains top spot
Danish pharmaceutical giant Novo Nordisk has seen a significant surge in the consumption of its weight-loss drug Wegovy in India following strategic price cuts introduced in November 2025.
The move, aimed at making the popular GLP-1 agonist therapy more accessible, resulted in a 70% increase in consumption within just 15 days. Despite these gains, rival Eli Lilly’s Mounjaro continues to dominate the Indian market, maintaining a substantial lead in sales and market share.
In mid-November, Novo Nordisk slashed prices for Wegovy by approximately 30-35%, reducing the cost of a dose from the ₹4,000–₹6,000 range to between ₹2,700 and ₹4,100. The highest dose of 2.4 mg is now priced at ₹16,400 for a monthly pack, down…
